{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:06:27Z","timestamp":1788051987925,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81101996"],"award-info":[{"award-number":["81101996"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Planned Science and Technology Project of Hunan Province, China","award":["2014FJ2015"],"award-info":[{"award-number":["2014FJ2015"]}]},{"name":"Chinese Anti-Cancer Association","award":["29"],"award-info":[{"award-number":["29"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ygyno.2017.12.013","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T06:43:57Z","timestamp":1513579437000},"page":"286-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["A phase II study of apatinib in patients with recurrent epithelial ovarian cancer"],"prefix":"10.1016","volume":"148","author":[{"given":"Mingming","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6121-2400","authenticated-orcid":false,"given":"Jie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.12.013_bb0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0010","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.critrevonc.2015.10.006","article-title":"Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; in the light of completed trials","volume":"98","author":"Korkmaz","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0015","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/ncponc1051","article-title":"Angiogenesis as a strategic target for ovarian cancer therapy","volume":"5","author":"Spannuth","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0020","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ncponc0905","article-title":"Mechanisms of disease: angiogenesis and the management of breast cancer","volume":"4","author":"Banerjee","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0025","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0030","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0035","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Errata: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/1471-2407-10-529","article-title":"Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies","volume":"10","author":"Jin","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2017.12.013_bb0045","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","author":"Li","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0050","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0055","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1358\/dot.2015.51.4.2320599","article-title":"Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors","volume":"51","author":"Scott","year":"2015","journal-title":"Drugs Today"},{"key":"10.1016\/j.ygyno.2017.12.013_bb0060","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2214\/AJR.09.3456","article-title":"Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy","volume":"194","author":"Smith","year":"2010","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0065","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","article-title":"Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels","volume":"19","author":"Rustin","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0070","doi-asserted-by":"crossref","unstructured":"Simon R. Optimal II stage designs for phase II clinical trials. Control. Clin. Trials 10: 1\u2013101989.","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"10.1016\/j.ygyno.2017.12.013_bb0075","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/13543784.2013.802769","article-title":"Sorafenib for ovarian cancer","volume":"22","author":"Maggiore","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ygyno.2017.12.013_bb0080","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/1078-0432.CCR-09-2308","article-title":"Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2","volume":"16","author":"Annunziata","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0085","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1593\/neo.09866","article-title":"The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma","volume":"11","author":"Cesca","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.ygyno.2017.12.013_bb0090","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2017.12.013_bb0095","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.ejca.2013.05.020","article-title":"A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer","volume":"49","author":"Liu","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.12.013_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13277-015-4781-4","article-title":"Cediranib in ovarian cancer: state of the art and future perspectives","volume":"37","author":"Ruscito","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0105","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/annonc\/mds003","volume":"23","author":"Baumann","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0110","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1186\/1471-2407-14-947","article-title":"Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study","volume":"14","author":"Ferrandina","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2017.12.013_bb0115","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1471-2407-11-214","article-title":"Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients","volume":"11","author":"Francesco","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2017.12.013_bb0120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ygyno.2009.02.018","article-title":"A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers","volume":"113","author":"Gupta","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2011.04.046","article-title":"Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers","volume":"122","author":"Kudoh","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0090-8258(03)00011-8","article-title":"Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer","volume":"88","author":"D'Agostino","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0135","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/jac\/dku069","article-title":"Activity of anti-cancer protein kinase inhibitors against Leishmania spp","volume":"69","author":"Sanderson","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ygyno.2017.12.013_bb0140","first-page":"367","article-title":"Inhibitory effect of apatinib on HCT-116 cells and its mechanism","volume":"37","author":"Yin","year":"2017","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.ygyno.2017.12.013_bb0145","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1186\/1471-2407-14-820","article-title":"Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer","volume":"14","author":"Hu","year":"2014","journal-title":"BMC Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817315962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817315962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T01:29:40Z","timestamp":1570498180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817315962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0090825817315962"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.12.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of apatinib in patients with recurrent epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}